Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Intratumoral Cancer Therapies Market Size Forecast: How Big Could The Market Get By 2030?
The intratumoral cancer therapies market has seen rapid growth in recent years. This market is expected to increase from $156.96 billion in 2025 to $174.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. The expansion observed during prior periods can be attributed to several factors, including restricted treatment specificity, a significant dependence on chemotherapy, insufficient adoption of immunotherapy, traditional tumor injection methods, and disparities in regional healthcare infrastructure.
The intratumoral cancer therapies market size is anticipated to undergo substantial expansion in the upcoming years. This market is projected to reach $274.76 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. The expansion during the forecast period is attributed to increased adoption of precision medicine, the growing use of immuno-oncology therapies, technological advancements in injection devices, heightened collaboration with biotech firms, and expanding cancer research funding. Prominent trends for the forecast period include targeted intratumoral drug delivery, combination therapy approaches, personalized cancer treatment, minimally invasive administration techniques, and enhanced tumor microenvironment modulation.
Get A Free Sample Report With In-Depth Market Insights:
Intratumoral Cancer Therapies Market Growth Catalysts And Demand Drivers
The expanding occurrence of cancer is projected to fuel the advancement of the intratumoral cancer therapies market in the future. Cancer refers to various conditions marked by the uncontrolled proliferation and dissemination of abnormal cells within the body. Intratumoral cancer therapies are employed for both the diagnosis and treatment of cancer, aiding in the prevention of off-target toxicities, dose-limiting toxicities, and immune stimulation-related adverse effects in patients. As an illustration, in January 2023, the American Cancer Society, a U.S.-based nonprofit cancer advocacy organization, estimated around 1,958,310 new cancer diagnoses for 2023 in the United States. This marks an increase of approximately 2.1% from the approximately 1,918,160 new cases recorded in 2022. Consequently, the rising prevalence of cancer is a key factor propelling the expansion of the intratumoral cancer therapies market.
Intratumoral Cancer Therapies Market Segment Trends And Revenue Contributors
The intratumoral cancer therapies market covered in this report is segmented –
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Peptide-Based Vaccines, Protein-Based Vaccines, DNA Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists
6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)
7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)
Intratumoral Cancer Therapies Market Trends Shaping Long-Term Demand
Leading companies in the intratumoral cancer therapies market are concentrating on developing innovative solutions, such as advanced oncolytic virus platforms, to address the increasing demand for precise tumor eradication, heightened immune activation, and next-generation localized cancer treatments. Oncolytic virus therapies are engineered viral constructs designed to selectively replicate within tumor cells, causing direct tumor lysis while simultaneously stimulating systemic anti-tumor immunity, thereby offering a more targeted and immune-potentiating alternative to traditional chemotherapy and radiation. For instance, in November 2024, Replimune Group, Inc., a U.S.-based clinical-stage biotechnology company, announced that its lead candidate RP1 (vusolimogene oderparepvec), an engineered herpes simplex virus armed with a fusogenic protein and GM-CSF, received Breakthrough Therapy Designation from the FDA, and its Biologics License Application was submitted under the Accelerated Approval pathway. This technology enables intratumoral delivery of an oncolytic virus that directly destroys tumor cells and amplifies systemic immune responses, representing a significant advancement in cancer treatment.
Intratumoral Cancer Therapies Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the intratumoral cancer therapies market are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Torigen Pharmaceuticals Inc.
View The Full Intratumoral Cancer Therapies Market Report:
Intratumoral Cancer Therapies Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the intratumoral cancer therapies market in 2025. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
